BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
15 mai 2020 07h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress
14 mai 2020 09h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Reports First Quarter 2020 Financial Results
11 mai 2020 16h05 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 11, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
29 avr. 2020 17h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
20 avr. 2020 16h05 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
13 avr. 2020 16h05 HE
|
BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
10 avr. 2020 18h00 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Supply Update for ABRAXANE® in China
25 mars 2020 09h00 HE
|
BeiGene, LTD.
- NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company - As the marketing agent for ABRAXANE in China, BeiGene...
BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results
02 mars 2020 16h05 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, March 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference
25 févr. 2020 07h00 HE
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...